BIT Capital GmbH Takes $629,000 Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Key Points

• BIT Capital GmbH acquired a new stake in Agios Pharmaceuticals by purchasing 21,468 shares valued at approximately $629,000 in the first quarter.
• Agios Pharmaceuticals reported a quarterly EPS of ($1.93), missing analysts' expectations, despite revenues of $12.50 million which exceeded expectations of $9.46 million.
• Company insider transactions included significant stock sales, with Director David Scadden selling 1,400 shares at an average price of $40.00, reducing their ownership by 7.37%.

BIT Capital GmbH acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 21,468 shares of the biopharmaceutical company's stock, valued at approximately $629,000.

Other institutional investors also recently modified their holdings of the company. Summit Investment Advisors Inc. increased its position in shares of Agios Pharmaceuticals by 7.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after purchasing an additional 394 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after acquiring an additional 499 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of Agios Pharmaceuticals by 4.4% in the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after buying an additional 582 shares in the last quarter. Alliancebernstein L.P. increased its stake in Agios Pharmaceuticals by 1.2% in the 4th quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock worth $2,021,000 after acquiring an additional 708 shares during the last quarter. Finally, Gallagher Fiduciary Advisors LLC lifted its stake in shares of Agios Pharmaceuticals by 7.6% in the 4th quarter. Gallagher Fiduciary Advisors LLC now owns 11,110 shares of the biopharmaceutical company's stock valued at $365,000 after purchasing an additional 788 shares during the last quarter.

Insider Transactions at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 1,780 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $59,701.20. Following the sale, the chief financial officer directly owned 30,049 shares of the company's stock, valued at approximately $1,007,843.46. This represents a 5.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Tsveta Milanova sold 2,770 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $92,905.80. Following the completion of the transaction, the insider directly owned 26,122 shares of the company's stock, valued at approximately $876,131.88. The trade was a 9.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,363 shares of company stock worth $1,619,654 over the last 90 days. 4.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

AGIO has been the topic of several research analyst reports. Bank of America cut their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Scotiabank lowered their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a report on Monday, July 28th. Finally, Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Agios Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $56.33.

Agios Pharmaceuticals Stock Down 1.4%

Shares of Agios Pharmaceuticals stock traded down $0.52 during trading on Thursday, reaching $37.21. The company's stock had a trading volume of 132,338 shares, compared to its average volume of 718,321. Agios Pharmaceuticals, Inc. has a 12-month low of $23.42 and a 12-month high of $62.58. The business has a 50 day moving average price of $36.07 and a 200-day moving average price of $32.66. The company has a market capitalization of $2.16 billion, a P/E ratio of 3.37 and a beta of 0.80.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. The company had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.46 million. Research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.